Pfizer announced results from its Phase 3 study comparing combination therapy of Vfend (voriconazole; Pfizer) and Eraxis (anidulafungin; Pfizer) to Vfend monotherapy for the treatment of invasive aspergillosis (IA). The primary analysis of this double-blinded, prospective, randomized, clinical trial was to compare mortality rates at six weeks after initiation of study treatment in patients with a diagnosis of proven or probable IA. Treatment with the combination of Vfend and Eraxis resulted in a lower all-cause mortality rate at six weeks compared to Vfend alone. However, this difference in mortality did not achieve the pre-specified threshold for statistical superiority. The safety and tolerability of the combination of Vfend and Eraxis in this study was similar to that of Vfend monotherapy.
Vfend IV/Oral is a broad-spectrum IV/oral triazole antifungal medication specifically indicated for the first-line treatment of both mold and yeast infections. Eraxis for Injection belongs to the echinocandin class of antifungal drugs and is used to treat serious fungal infections caused by Candida.